Drug intelligence / Profile preview

ATG-115

Development stage: Preclinical
Lead developer: Antengene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ATG-115 is an investigational bispecific T-cell engager (TCE) being developed by Antengene for the treatment of liver cancer. Utilizing the company's proprietary AnTenGager™ TCE 2.0 platform, ATG-115 is engineered to simultaneously bind to the CD3 receptor on T cells and an undisclosed tumor-associated antigen expressed on liver cancer cells. This dual binding facilitates the formation of an immunological synapse, redirecting the cytotoxic activity of T cells to selectively target and lyse tumor cells. ATG-115 is part of Antengene's portfolio of next-generation immunotherapies aimed at addressing unmet needs in oncology.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ATG-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATG-115.

Explore the full profile